Trevena, Inc.

288 articles about Trevena, Inc.

• Trevena Reports Second Quarter 2021 Results

  8/12/2021

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, reported its financial results for the second quarter ended June 30, 2021 and provided an overview of its recent operational highlights.

• Trevena Announces Publication Highlighting Risk / Benefit Analysis of OLINVYK® in Pain and Therapy

  8/10/2021

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced the publication of an exploratory analysis evaluating the safety of OLINVYK injection and IV morphine, using data from the OLINVYK Phase 3 program.

• Trevena to Release Second Quarter 2021 Financial Results on August 12th, 2021

  8/9/2021

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that it will release its financial results for the second quarter ended June 30, 2021, prior to the market open on Thursday, August 12th, 2021.

• Trevena Announces First Patient Enrolled in NIH-Funded ACTIV-4 Host Tissue Trial of TRV027 for COVID-19

  7/26/2021

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that the first COVID-19 patient has been enrolled in the NIH-funded ACTIV-4 Host Tissue trial.

• Trevena Announces Two Leading Independent Proxy Advisory Firms Recommend Shareholders Vote “For” All Proposals Ahead of Special Meeting of Stockholders

  7/23/2021

  Glass Lewis and Institutional Shareholder Services (ISS) independently recommend that Trevena shareholders vote “FOR” proposals to approve a Reverse Stock Split and concurrent Authorized Share Reduction

• Trevena Announces Publication of OLINVYK® Health Economic Model in Journal of Comparative Effectiveness Research

  7/12/2021

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced the publication of the health economic model for OLINVYK injection in Journal of Comparative Effectiveness Research.

• Trevena Announces First Patient Enrolled in OLINVYK® Phase 3 Trial in China in Partnership with Jiangsu Nhwa Pharmaceutical

  7/8/2021

  Trevena, Inc. today announced the Company’s partner in China has enrolled the first patient in a Phase 3 trial for OLINVYK (oliceridine) injection, a novel IV analgesic approved in the U.S. by the Food and Drug Administration (FDA) for acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.

• Trevena Announces Initiation of OLINVYK® Respiratory Physiology Study Including Elderly / Obese Subjects

  7/7/2021

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced it has initiated a new study evaluating the physiologic impact of OLINVYK on respiratory function in elderly / obese subjects.

• Trevena Added to Russell 2000®, Russell 3000®, and Russell Microcap® Indexes

  6/28/2021

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced it has been added to the small-cap Russell 2000® Index, the broad-market Russell 3000® Index, and the Russell Microcap® Index, effective after the U.S. equity markets open, Monday, June 28th, 2021.

• Trevena Announces NIH Has Resumed Recruiting Patients in Proof-of-Concept Study for TRV734 in Opioid Use Disorder

  6/16/2021

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that NIDA has resumed recruiting patients for its proof-of-concept study for TRV734, the Company’s novel mu-opioid receptor selective agonist.

• Trevena to Present at the JMP Securities Life Sciences Conference

  6/9/2021

  Trevena, Inc. announced that Carrie Bourdow, President and Chief Executive Officer of Trevena, Inc. will participate in a fireside chat at the JMP Securities Life Sciences Conference being held virtually June 16 - 17, 2021.

• Trevena Announces Presentations of OLINVYK® Health Economic Models at ISPOR 2021

  5/19/2021

  Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced two poster presentations at the International Society for Pharmacoeconomics and Outcomes Research

• Trevena Announces Presentation of OLINVYK® Respiratory Safety Data in High-Risk Patients at the 46th Annual ASRA Meeting

  5/12/2021

  Elderly and obese patients receiving OLINVYK are not at increased risk for respiratory depression, compared to younger and non-obese patients, based on exploratory analysis

• Trevena Announces TRV027 Selected by NIH-Funded ACTIV Initiative For COVID-19 Trial

  5/6/2021

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that TRV027, the Company’s novel AT1 receptor selective agonist, has been selected for an NIH ACTIV trial in COVID-19 patients.

• Trevena to Release First Quarter 2021 Financial Results on May 6, 2021Company to host conference call on May 6, 2021, at 8:00 a.m. ET

  5/5/2021

  Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the first quarter ended March 31, 2021, prior to the market open on Thursday, May 6, 2021. Company management will host a conference call and webcast to discuss its financial results

• Trevena, Inc. to Participate at the Sachs Associates 4th Annual Neuroscience Innovation Forum

  4/29/2021

  Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark A. Demitrack, M.D., Senior Vice President and Chief Medical Officer, will be participating at the 4th Annual Sachs Associates Neuroscience Innovation Forum taking place from Wednesday, April 28 to Friday, April 30, 2021.

• Trevena Announces TRV027 Selected for Study in Global REMAP-CAP Trial in COVID-19 Patients

  4/21/2021

  -- REMAP-CAP is led by experts in pandemic response and builds upon a worldwide clinical trial network evaluating treatments for COVID-19 Interim review of Imperial College London TRV027 study data supports transition to larger study

• Trevena, Inc. Announces Presentations of OLINVYK™ Health Economic Models at AMCP 2021 Annual Meeting

  4/15/2021

  Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced two poster presentations at the AMCP 2021 Annual Meeting.

• Trevena, Inc. Reports Fourth Quarter and Full Year 2020 Results

  3/9/2021

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, reported its financial results for the fourth quarter and full year ended December 31, 2020, and provided an overview of its 2020 and 2021 year-to-date operational highlights.

• Trevena to Release Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021

  3/5/2021

  Trevena to host conference call on March 9 th , 2021, at 8:00 a.m. ET --